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Neutralizing Antibodies Have Limited
Effects on the Control of
Established HIV-1 Infection In Vivo
concentration, the Ab might have little effect in control-
ling infection if the establishment of infection was not
blocked. To directly address the question of whether
Ab can impact the course of an ongoing HIV-1 infection,
we decided to study in detail the consequences of pas-
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The Scripps Research Institute infection using the hu-PBL-SCID mouse model. We used
La Jolla, California 92037 the only three human mAbs, b12, 2G12, and 2F5 (Muster
² Institute of Applied Microbiology et al., 1993; Burton et al., 1994; Trkola et al., 1996),
University of Agriculture known to have a potent neutralizing activity against a
1190 Vienna broad range of primary isolates (Burton and Montefiori,
Austria 1997; D'Souza et al., 1997). We reasoned that if high
serum concentrations of these neutralizing Abs do not
influence the course of HIV infection in the mouse model,
then it is unlikely that neutralizing Abs at the levels foundSummary
in natural infection would impact the course of infection
in humans. This would help clarify the still unclear roleNeutralizing antibodies can protect against challenge
of humoral immunity in the control of HIV-1 in infectedwith HIV-1 in vivo if present at appropriate concentra-
individuals.tions at the time of viral challenge, but any role in the
control of established infection is unclear. Here, we
show that high serum concentrations of neutralizing
Resultsmonoclonal antibodies, either singly or as a cocktail,
have little sustained effect on viral load in established
HIV-1 infection in hu-PBL-SCID mice. In some in- The Administration of a Single Neutralizing mAb
stances, virus replication of neutralization-sensitive Does Not Control HIV-1 Replication In Vivo
virus continues even in the presence of high levels of Initial experiments focused on the activity of the human
neutralizing antibody. In most instances, neutraliza- mAb b12 on an established HIV-1 infection. Fifteen re-
tion escape occurs in a few days, even from a cocktail constituted hu-PBL-SCID mice were infected intraperi-
of three antibodies that recognize distinct epitopes. toneally (i.p.) with HIV-1JR-CSF, a molecularly cloned HIV-1
The results imply that humoral immunity is unlikely to primary R5 virus that is sensitive to b12 neutralization
play a significant role in the control of established in vitro (90% neutralization titer 5 5 mg/ml). After 5 days,
HIV-1 infection in humans. viral RNA could be detected in the mouse plasma using
RT-PCR. At day 6, five mice were treated i.p. with 50
mg/kg of b12. This dose of b12 has been shown to
Introduction completely protect hu-PBL-SCID mice against chal-
lenge with HIV-1JR-CSF if given up to 8 hr post viral chal-
The classical and most definitive approach to establish- lenge (Gauduin et al., 1997). The injection results in an
ing antiviral activities of antibody (Ab) is through passive initial serum concentration of about 500 mg/ml that de-
immunization studies. Such studies have shown that cays with a half-life of a week (Parren et al., 1995). There-
Abs capable of in vitro neutralizing activity can protect fore, the initial Ab concentration is about 100-fold higher
against challenge with neutralization-sensitive T cell line than the 90% in vitro neutralization titer and is still about
adapted strains of HIV-1 in chimpanzees and in hu-PBL- 10-fold higher after a period of 3 weeks. Five control
SCID mice (Safrit et al., 1993; Gauduin et al., 1995; Parren mice were given no treatment and another 5 mice were
et al., 1995; Andrus et al., 1998). Protection against pri- given 50 mg/kg of a normal polyclonal human IgG prepa-
mary isolates has been less studied and is more difficult ration. Plasma viral RNA levels were assessed over time
to demonstrate, correlating with the relative resistance by quantitative RT-PCR (Roche HIV Amplicor assay).
of these isolates to in vitro neutralization (Moore and In most mice, including controls, viral loads fell before
Ho, 1995). Nevertheless, recently a potent human mono- leveling off between days 7 and 13 after virus inocula-
clonal Ab (mAb) (b12) has been shown to protect against tion. Five mice with detectable viral loads at day 7 were
HIV-1 primary isolate challenge in the hu-PBL-SCID mouse
followed further. In these mice, viral load levels were
model (Gauduin et al., 1997). Protection was observed
maintained for at least 5 weeks (data not shown). Most
even when Ab was given several hours post viral expo-
strikingly, there were no significant differences in eithersure. However, when breakthrough occurred, the titer
the initial rate of decrease or the plateau levels of viralof the infectious virus was as high in treated animals as
RNA between the b12-treated and the control mice (Fig-in control animals, indicating that, despite a high serum
ure 1A).
Next, the experiment was repeated with a second R5
primary virus, HIV-1SF162. The kinetics of replication of³ To whom correspondence should be addressed (e-mail: burton@
scripps.edu). this virus in the hu-PBL-SCID mouse model differ in that
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Figure 1. Plasma Levels of HIV-1 RNA Mea-
sured by Quantitative RT-PCR in HIV-1-
Infected hu-PBL-SCID Mice after Administra-
tion of the Neutralizing Ab b12
Hu-PBL-SCID mice with a HIV-1JR-CSF (squares)
or HIV-1SF162 (circles) isolate infection were in-
jected i.p. with 1 mg of b12 (solid symbols)
or control Ab (open symbols). Mice received
a single injection at day 0 (A and B) or multiple
injections at days 0, 5, and 10 (C and D). In
(A) and (B), mice were treated 6 days after
viral infection. In (C) and (D), mice were
treated when viral steady state was reached,
8 and 10 days after viral infection for HIV-1SF162
and HIV-1JR-CSF, respectively. The vertical
arrows indicate days of Ab injection. Each
curve represents the values for a single ani-
mal. Blood was obtained by bleeding from
the orbital sinus of the mice. Plasma HIV-1
RNA levels were measured by the quantita-
tive Roche RT PCR assay (Amplicor HIV Mon-
itor, Roche Molecular Systems), following the
manufacturer's recommended protocol, ex-
cept that plasma volume was 100 ml. The limit
of HIV-1 RNA detection, as indicated by the
horizontal arrow, was 400 copies/ml.
the viral RNA levels tend to plateau earlier and at higher b12. Out of seven HIV-1JR-CSF isolates rescued from neu-
tralizing Ab-treated mice, four displayed a complete re-levels than following HIV-1JR-CSF infection. Another differ-
ence is that HIV-1SF162 is more sensitive to neutralization sistance to b12 neutralization at concentrations as high
as 50 mg/ml. In contrast, isolates rescued from normalby b12 than HIV-1JR-CSF (90% neutralization titer 5 1 mg/
ml). A 50 mg/kg dose of Ab now results in a serum human IgG-treated mice remained sensitive to b12 at
levels similar to the original HIV-1JR-CSF (Figure 2A). Ofconcentration about 500-fold higher than the in vitro
90% neutralization titer. Although the viral load dropped note, three isolates rescued from b12-treated mice dis-
played a neutralization sensitivity similar to control iso-to undetectable levels in one b12-treated mouse, again
there was no overall significant difference between b12- lates. From six HIV-1SF162 isolates that were rescued from
b12-treated mice, five displayed a marked increase intreated and control mice (Figure 1B).
To verify that the lack of effect of b12 administration resistance to b12 neutralization (Figure 2B). The re-
maining isolate was as sensitive to b12 neutralizationwas not due to decrease of Ab concentration under a
neutralization threshold, we studied the effect of multi- as control isolates.
ple injections of b12. In order to better make evident an
eventual impact of Ab administration, we decided to
administer b12 when the viral load had stabilized. Two The Neutralization Escape Mutants Display Envelope
mice were injected starting 10 days after HIV-1JR-CSF in- Mutations Consistent with Their Phenotype
fection and two additional mice were injected starting To determine if changes in b12 neutralization phenotype
8 days after HIV-1SF162 infection. Infected hu-PBL-SCID were associated with genotypic changes, we derived
mice received three injections of 50 mg/kg of b12, one sequences corresponding to the entire V1 to C4 regions
every 5 days, and were then followed over 15 days. of gp120 from isolates rescued from treated and control
Control animals received injections of purified normal mice. All the isolates that displayed in vitro resistance
human IgG at the same dose. As shown in Figures 1C to b12 neutralization had 1±3 mutations compared to
and 1D, in all b12-treated animals the viral load remained the wild-type sequence, including mutations in each
stable or increased over time, despite Ab plasma levels case in a region known to be involved in the CD4 binding
maintained at above 250 mg/ml for 15 days. site and in the b12 epitope (these were P365Q, P365T,
M369R, P365Q and M369R, and V368A). Detailed analy-
sis of b12 escape mutation patterns will be given inThe Viruses Rescued from Neutralizing Ab-Treated
a further report. Therefore, envelope sequences wereMice Are Mostly, but Not Exclusively,
consistent with the observation that these isolates wereNeutralization Escape Mutants
neutralization escape mutants. Of note, out of fourThe lack of effect of b12 could reflect the rapid develop-
HIV-1JR-CSF and three HIV-1SF162 escape mutant env genesment of Ab neutralization escape mutants. To investi-
sequenced, none showed the same pattern of mutation,gate this possibility, viruses were rescued from b12-
suggesting that multiple genotypes can lead to b12treated mice by in vitro coculture with fresh activated
human PBL and assayed for in vitro neutralization with escape. The escape viruses were rescued from mice
Neutralizing Abs in Established HIV Infection
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Figure 2. In Vitro Neutralization of HIV-1 Iso-
lates Rescued from b12-Treated hu-PBL
SCID Mice
In vitro neutralization by mAb b12 of isolates
rescued from HIV-1JR-CSF (squares)- or HIV-1SF162
(circles)-infected hu-PBL-SCID mice, treated
previously with mAb b12 (solid symbols) or
control Ab (open symbols, inset graphs).
sacrificed as early as 7 days after b12 injection, sug- of plasma virus decay following anti-CD4 treatment. De-
cay was exponential in all mice, and a simple linear regres-gesting that neutralization escape mutants were se-
lected within a week after b12 injection. Sequencing of sion analysis as in Ho et al. (1995) gave viral decay
slopes in the range of 20.20 to 20.54 per day, veryproviral DNA from tissues of sacrificed animals gave
identical results, confirming the rapid in vivo selection comparable to those observed in humans treated with
protease inhibitors. Therefore, viral turnover in humansof escape mutants.
and the mouse model appears to be similar.
The Kinetics of Plasma HIV-1 Turnover
in the hu-PBL-SCID Mouse Model The Injection of a Cocktail of Three Neutralizing
mAbs Does Not Control HIV-1 Replication In VivoTo calculate the decay rate of plasma virus in the hu-
PBL SCID mouse and to verify that i.p. administration We then reasoned that a cocktail of neutralizing Abs
directed against distinct epitopes would likely be moreof an Ab can lead to detectable effects on viral load
in this model, we treated mice with an anti-CD4 mAb effective at controlling HIV replication and at preventing
the development of escape mutants. Three HIV-1JR-CSF-capable of blocking HIV infection. Administration of the
humanized anti-CD4 Ab OKTcdr4a (Pulito et al., 1996) infected hu-PBL-SCID mice were treated with one i.p.
injection of 1 mg each of b12, 2G12, and 2F5 (50 mg/to mice with an established HIV-1 infection dramatically
dropped the viral load to undetectable levels in 1 to 5 kg each). These three mAbs are capable of neutralizing
HIV-1JR-CSF in vitro (the in vitro 90% neutralization titersdays in all of the treated mice (Figure 3), showing that
an i.p. injected Ab can efficiently target HIV-producing for the virus used are 5, 100, and 30 mg/ml for b12, 2G12,
and 2F5, respectively). Therefore, injection of 50 mg/kgcells and that viral turnover in the hu-PBL-SCID mouse
model can allow the detection of a decrease in virus of each Ab resulted in an initial plasma concentration
approximately 100-, 5-, and 16-fold higher than the inproduction following treatment. To verify that the rapid
appearance of neutralization escape mutants following vitro 90% neutralization titer for b12, 2G12, and 2F5,
respectively. In one mouse, the viral load dropped toAb treatment was relevant to human infection and not
the consequence of a much faster viral turnover in the undetectable levels and remained undetectable (Figure
4A). In the other two mice, the viral load rapidly droppedmouse model than in humans, we analyzed the kinetics
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mutations (N388D) and (P365Q) consistent with escape
from 2G12 and b12, respectively (Trkola et al., 1996;
Mo et al., 1997). The ELDKWA epitope, that strongly
correlates with 2F5 neutralization (D'Souza et al., 1997),
was unchanged in the isolate with a 2F5 resistance phe-
notype. However, a lys→glu mutation was found close
to the ELDKWA epitope that may be associated with
resistance (Figure 4C).
The Kinetics of Appearance of the Triple
Neutralization Escape Variant
To study the kinetics of appearance of the triple escape
variant T1, we analyzed plasma viral RNA from the corre-
sponding Ab cocktail-treated mouse. The C4 to V4 re-
gion of gp120 that includes mutations consistent with
b12 and 2G12 escape was amplified and sequenced
from plasma viral RNA taken at different time points
(Figure 5). On the day of Ab injection, all clones analyzed
displayed wild-type sequence. By day 5, 25% of the
clones displayed the mutant genotype, and by day 7 all
clones analyzed displayed the mutant genotype. The
appearance of the escape mutant genotype is coinci-
dent with the rebound in viral load that begins at day
5 (Figure 4A). By day 13, the wild-type genotype has
reemerged to once again become the predominant spe-
cies. It is presumed that the reemergence of the wild-
type genotype reflects a decline in Ab levels and there-
Figure 3. Plasma Levels of HIV-1 RNA in HIV-1-Infected hu-PBL- fore that a high Ab concentration must be maintained
SCID Mice after Anti-CD4 Ab Administration to favor selection of the 2G12/b12 escape mutants.
The horizontal arrow indicates the limit of HIV-1 RNA detection (400
copies/ml). Each curve represents the values for a single animal.
(A) Hu-PBL-SCID mice with an established HIV-1JR-CSF isolate infec- Discussion
tion were injected intraperitoneally at day 0 with 1 mg of OKTcdr4A
(solid symbols) or control Ab (open symbols). (B) Hu-PBL-SCID mice In order to study the impact of neutralizing Abs on an
with an established HIV-1SF162 isolate infection were injected intra- ongoing HIV-1 infection, we have administered potent
peritoneally at day 0 with 1 mg of OKTcdr4A (solid symbols) or were
neutralizing Abs to HIV-1-infected hu-PBL-SCID miceleft untreated (open symbols).
after the infection had been established for some days,
in most cases when the viral load had reached steady
state levels. Our results show that passive administra-but increased again at day 5, to reach initial levels at
day 7. This shows that HIV can replicate in vivo despite tion of either a single neutralizing human mAb or of a
cocktail of three such Abs has minimal effect on thethe presence of a combination of neutralizing Abs at
concentrations higher than the in vitro 90% neutraliza- control of an ongoing HIV-1 infection in the hu-PBL-
SCID mouse model. Following Ab administration, intion concentrations.
some instances the virus remains sensitive to Ab neu-
tralization, but in most instances a neutralization escapeA Virus that Escapes a Cocktail of Three
Neutralizing Abs Is Selected In Vivo mutant is rapidly selected. This suggests, together with
the reemergence of wild-type virus as Ab concentrationViruses were rescued from both mice and tested in vitro
for neutralization by 2G12, b12, and 2F5. As shown in wanes as described above, that the Ab dose used in
the experiments results in an in vivo concentration closeFigure 4B, the two isolates T1 and T2 rescued from the
cocktail-treated mice displayed a variable resistance to to the threshold required to exert sufficient pressure on
the virus in order to induce neutralization escape. Theneutralization by all three Abs. One isolate (T2) displayed
a phenotype resistant to neutralization by 2G12, while selection of Ab escape mutants depends on the strength
of Ab-mediated pressure, the rate of viral turnover, andremaining sensitive to neutralization by b12 and 2F5.
Most strikingly, the other isolate (T1) displayed a resis- on the potential escape mutant fitness (Coffin, 1995).
For a minority of Ab-treated mice, the Ab-mediated pres-tant phenotype to all three Abs. This demonstrates that
a variant able to escape the three most potent anti- sure in combination with the other two factors is not
sufficient to result in neutralization escape. These miceHIV-1 Abs described to date can be rapidly selected in
vivo. To verify whether the phenotypic changes were have the highest viral loads and presumably this in-
creases the threshold of Ab concentration required forassociated with genotypic modifications, the whole env
gene of both isolates was sequenced. As shown in Fig- neutralization escape.
For the majority of mice in the study, the Ab-mediatedure 4C, sequencing revealed that one isolate (T2) dis-
played mutations (N336D and T338I) compatible with pressure, in combination with the other factors, is suffi-
cient to rapidly lead to the selection of escape mutants.2G12 escape, whereas the other isolate (T1) displayed
Neutralizing Abs in Established HIV Infection
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Figure 4. Treatment of HIV-1JR-CSF-Infected
hu-PBL-SCID Mice with a Cocktail of Neu-
tralizing Abs
(A) Plasma levels of HIV-1 in HIV-1JR-CSF-
infected hu-PBL-SCID mice after administra-
tion of a cocktail of neutralizing Abs (b12,
2G12, and 2F5). Ab was administered 11 days
after viral infection. The time of Ab injection
is indicated by the arrow at day 0 in the figure.
Each curve represents the values for a single
animal. M1 and M2 indicate the mouse from
which the isolates T1 and T2 were rescued,
respectively. Plasma HIV-1 RNA levels were
measured by the quantitative Roche RT PCR
assay (Amplicor HIV Monitor, Roche Molecu-
lar Systems), using a plasma volume of 50 ml.
The limit of detection, as indicated by the
horizontal arrow, was 800 copies/ml.
(B) In vitro neutralization by (1) 2F5, (2) 2G12,
and (3) b12 of the challenge virus HIV-1JR-CSF
(closed square) and the viral isolates T1
(closed triangle) and T2 (open triangle) iso-
lated from infected hu-PBL-SCID mice fol-
lowing treatment with a cocktail of the Abs
2F5, 2G12, and b12 (see [A]).
(C) Deduced amino acid sequence of the C3,
V4, and gp41 regions of gp160 from wild-type
(WT) JR-CSF virus and escape variants T1
and T2 following triple Ab therapy (see [A]
and [B]).
Two hypotheses can be envisaged: (1) the escape vari- glycoprotein every day. Escape from neutralizing Abs
only requires 1±3 mutations, and several mutation pat-ants were present in the viral inoculum and then se-
lected; (2) they were rapidly generated during the ongo- terns can lead to escape from the same Ab. Since vari-
ants with replication advantage can rapidly take overing infection and then selected under Ab pressure. We
favor the second hypothesis, since, in one set of experi- (Coffin, 1995), viral escape is then possible within a short
time.ments, we used the molecularly cloned virus HIV-1JR-CSF,
and because several different escape viral variants were In most cases, Ab escape seems to occur at limited
cost to the virus as replicative capacities of escapeobtained following treatment with the same Ab.
The appearance of escape mutants in a few days in mutants and wild-type viruses are similar. Some differ-
ences are apparent. In particular, the triple escape mu-the mouse model is consistent with known features of
viral mutation. In hu-PBL-SCID mice, about 5% of CD4 tant described does not appear as fit as the wild-type
virus, as shown by rapid reversion to wild-type as AbT cells, i.e., about 5 3 104 to 1 3 105 CD4 T cells, are
infected as shown by in situ hybridization studies concentration wanes. However, it should be noted that
viruses resistant to all three mAbs used have been char-(D. E. M., unpublished data). The half-life of infected
CD4 T cells has been shown to be approximately 1.2 acterized in natural infection (Parren et al., 1998b), sug-
gesting that such viruses are sufficiently fit to replicatedays (Perelson et al., 1996). A similar half-life of infected
cells in the SCID mouse model has been suggested by in man. The interplay between the wild-type and the
mutant virus shows the remarkable flexibility of HIV-1the work of Pettoleo-Mantovani et al. (1998) and our
own results (D. E. M., unpublished data). Therefore, it in face of selective pressure. Of further note, in our
experiments the Ab-mediated pressure is never suffi-can be hypothesized that about 3 3 104 cells are infected
every day in a hu-PBL-SCID mouse. The mutation rate cient (with one statistically nonsignificant possible ex-
ception) to reduce viral loads below the detection levelof HIV-1 is approximately 1 3 1024/bp. Therefore, in
the env gene, about three mutations per bp should be except transiently. It has now been well demonstrated
that only antiviral drug treatments that have a profoundgenerated every day in the mouse. This can be approxi-
mated to one mutation per amino acid of the envelope effect on viral replication can prevent the appearance
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the neutralization potency of Abs in infected humans is
much less than following Ab administration in the mouse
model. In sera from HIV-1-infected individuals, Ab neu-
tralization titers are typically low (Pilgrim et al., 1997).
Moreover, contemporaneous autologous isolates are
rarely neutralized effectively (Pilgrim et al., 1997). In con-
trast, in the mouse model, serum neutralization titers
following Ab administration are high and the contempo-
raneous virus is truly sensitive to neutralization by the
Ab used. Further, we have previously shown that a pool
of immune globulin from HIV-1-infected patients (HIVIG)
is less potent at protecting hu-PBL-SCID mice against
Figure 5. Interplay between Wild-Type and Neutralization Escape HIV-1 primary isolate infection than the mAb b12 (Gau-Viruses upon Ab Treatment
duin et al., 1997) and is therefore likely to have even
The C4 to V4 region of gp120 that includes mutations consistent
less impact on an established HIV-1 infection. All thesewith b12 and 2G12 escape was amplified and sequenced from
arguments indicate that HIV-1-neutralizing Ab levels inplasma viral RNA from the T1 variant (Figure 4) taken at different
humans will not reach the threshold needed to put signif-time points. The bars represent the percentage of clones displaying
either the wild-type sequence (gray) or the escape mutant sequence icant pressure on the virus. In agreement with this point
(black). The number of clones sequenced was 5, 4, 11, and 12 at of view, analysis of autologous neutralizing Ab re-
day 0, 5, 7, and 13, respectively. The line represents the approximate sponses in HIV-1-infected individuals has recently led
Ab concentration (b12 concentration 5 2G12 concentration) in the
Schùnning et al. (1998) to question the efficiency ofmouse plasma estimated from the known pharmacokinetics of the
neutralizing Abs in the control of HIV-1 infection, and toAbs and checked as total Ab concentration at initial and mid-point
suggest that earlier observations of neutralization es-by ELISA reactivity with gp120.
cape in patients may be epiphenomena (Albert et al.,
1990; Tremblay and Wainberg, 1990; Arendrup et al.,
1992).of resistance (Gunthard et al., 1998). The observed very
Rare HIV-1-infected individuals appear to have rela-rapid emergence of escape variants in Ab-treated mice
tively high neutralizing Ab titers in their sera. In suchis likely associated with the inability of neutralizing Abs
individuals, neutralizing Ab level may reach the concen-to have an effect on viral replication as profound as
tration threshold we have established here for exertingthat exerted by drug combinations. One caveat to these
pressure on the virus. However, neutralization escapeconsiderations, as suggested by the work of Van Rom-
is likely to occur even more easily in these individualspay et al. (1998), is that the Ab half-life could be shorter
than in the mouse model because viral diversity in hu-following administration to HIV-1-infected animals com-
man infection should be far greater than in the modelpared to uninfected that could potentially diminish their
permitting easier neutralization escape. In humans, di-efficiency. However, our estimation of b12 and 2G12
versity is established over years during an ongoing infec-
concentration at days 3, 5, and 7 following Ab-cocktail
tion, whereas, in many of our experiments in the mouse
administration does not indicate that the half-life of
model, infection was only recently established by a mo-
these two Abs was shortened by injection into HIV-1-
lecular clone. Furthermore, in humans the number of
infected animals (Figure 5; data not shown). infected cells is much higher than in hu-PBL-SCID mice.
Ab serum concentrations achieved in mice following Since viral turnover in the model and HIV-1-infected
i.p. injection are typically of one order of magnitude or individuals is similar, the ongoing generation of viral
more greater than the in vitro concentrations required diversity in humans should be far greater, facilitating
to fully neutralize the HIV-1 isolates used in this study. neutralization escape. This remains valid even consider-
Therefore, the free virus present in mice at the time of ing that most CD4 T cells are activated and susceptible
Ab administration is mostly if not completely neutralized. to infection in the hu-PBL-SCID mouse model.
The limited impact of Ab administration on viral replica- One caveat is that in the mouse model, Ab effector
tion in the hu-PBL-SCID mouse model then suggests functions such as complement activation and Ab depen-
that HIV-1 propagation in vivo must be mediated to dent cellular cytotoxicity (ADCC) are suboptimal. These
varying degrees by routes other than free virus, most functions may lead to some underestimation of the effi-
probably via cell-to-cell spread. Blocking of cell-to-cell cacy of Abs in human. However, our data also suggest
transmission generally requires Ab concentrations con- that neutralization escape occurs mostly by mutations
siderably higher than those needed to block free virus that reduce Ab binding to the viral envelope glyco-
entry (Pantaleo et al., 1995), explaining why the virus is proteins, which would also allow the virus to escape
able to replicate in the presence of relatively high Ab Ab-mediated complement lysis and ADCC as well as
concentrations. In mice where Ab administration has no neutralization. In conclusion, the results imply that anti-
effect on virus replication and there is no evidence of bodies at levels found in natural infection are unlikely
neutralization escape, it would seem that infection is to play a significant role in the control of HIV-1 infection
propagated mainly independently of free virus, which is in humans. Finally, the data presented here, using the
then largely a reflection of viral production by infected currently most potent available HIV-1-neutralizing mAbs
cells. (D'Souza et al., 1997), suggest that antibody-based ther-
A number of considerations suggest that Abs are un- apeutics face considerable hurdles. Abs of higher affin-
likely to be more effective in HIV-1 infection in humans ity for mature oligomeric envelope glycoproteins and
therefore higher neutralizing potency (Sattentau andthan in the mouse model used here. Most importantly,
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AntibodiesMoore, 1995; Parren et al., 1998a) would be desirable
The production of human mAbs b12, 2G12, and 2F5 has been de-especially if they could interrupt cell-to-cell spread.
scribed previously (Burton et al., 1991, 1994; Muster et al., 1993;These data also do not support the use of therapeutic
Trkola et al., 1996). The human mAb b12 recognizes a discontinuous
vaccines solely based on neutralizing Abs, at least until epitope overlapping the CD4 binding site on gp120 (Roben et al.,
neutralizing Ab titers higher than those elicited by natu- 1994). The human mAb 2G12 recognizes a conformationally sensi-
tive gp120 epitope unrelated to the V1, V2, V3, and CD4 bindingral infection can be obtained by vaccination. The data
site (Trkola et al., 1996) 2F5 is an anti-gp41 human mAb that hasfurther suggest that a vaccine based solely on Ab would
been mapped to the ELDKWA sequence (Muster et al., 1993).need to provide sterilizing immunity since even a low
level of HIV-1 replication could lead to escape from
Env SequencesAb neutralization and the spread of a vaccine-resistant
Proviral DNA was extracted from infected PBMCs or hu-PBL-SCID
virus. mouse tissue by standard procedures. To analyze gp120 sequence
from the virus isolates present, PCR was performed to amplify the
entire V1 to C4 regions of gp120 using the following primers:Experimental Procedures
59-TATGGGATCAAAGCTTAAAGCC-39 (nt 6564 to 6585, sense) and
59-GCCTTGGTGGGTGCTACTC-39 (nt 7695 to 7713, anti-sense). ToGeneration of hu-PBL-SCID Mice
analyze the genotype of isolates from Ab cocktail-treated mice, theA breeding colony of CB-17 SCID mice, maintained under specific
entire HIV-1JR-CSF gp160 was amplified by PCR using four primerspathogen-free conditions at The Scripps Research Institute, was
with overlaps in sequence. The C1 to C3 regions were amplifiedused as source of animals for these studies. Mice of the non-leaky
using the following primers: 59-ATCAGCACTTGTGGAAAGGG-39 (ntphenotype (mouse IgM serum level ,5 mg/ml) were reconstituted
6264 to 6283, sense) and 59-TCAGTGCCACTTGACTTTTCA-39 (ntby i.p. injection of 25 3 106 normal human PBMC, as described
7417 to 7437, anti-sense). The gp120 V4 to gp41 regions were ampli-previously (Mosier et al., 1993). Two weeks after reconstitution,
fied using the following primers: 59-TGAAAAGTCAAGTGGCACTGA-39mouse sera were tested for the presence of human immunoglobulin.
(nt 7417 to 7437, sense) and 59-CCTTACAGTAGACCATCCAGGC-39Only human immunoglobulin-positive mice were used for HIV-1 in-
(nt 8813 to 8834, anti-sense).fection. Each experiment used mice reconstituted with cells from a
To study the genotype of circulating virus, RNA was extractedsingle donor. All procedures for maintenance and injection of the
from mouse plasma using the Qiagen viral RNA kit (Qiagen). RNAhu-PBL-SCID mice were performed in a biosafety level 3 facility, in
was reverse transcribed to cDNA (1st strand cDNA synthesis kit,accordance with The Scripps Research Institute guidelines.
Boehringer Mannheim). cDNA was amplified from C4 to the begin-
ning of V4 gp120 regions using the following primers: 59-AGGACCAG
HIV-1 Virus Stocks GGAGAGCATTTT-39 (sense, nt 7156 to 7175) and 59-TCAGTGCCAC
Virus stocks were made by infection of PHA-stimulated PBMCs. TTGACTTTTCA-39 (nt 7417 to 7437, anti-sense).
Virus was recovered after 5±7 days of culture and the median tissue PCR products were cloned using the TOPO TA Cloning Kit (In-
culture infectious dose per milliliter (TCID50/ml) was determined by vitrogen). Double stranded plasmid DNA was isolated from 5 to
end-point dilution. Mice were infected with 1000 TCID50. The follow- 10 clones using a Qiagen Quickspin kit (Qiagen). Sequences were
ing HIV-1 primary isolates were used in this study: HIV-1SF162 (Cheng- obtained by automated sequencing (ABI, Perkins-Elmer).
Mayer and Levy, 1988), a R5 isolate, and HIV-1JR-CSF, a molecularly
cloned R5 virus (Koyanagi et al., 1987), obtained from the National Acknowledgments
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